A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
The main purpose of this study is to assess preliminary efficacy and safety of CFZ533 and LYS006 in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533 and LYS006 have an adequate clinical profile for further clinical development.
Jul 22, 2020
Feb 27, 2019
Dec 28, 2022
18 Years - 65 Years (Adult, Older Adult)
Placebo to CFZ533
Placebo to LYS006
Patients with moderate to severe HS based on the number of lesions, fistulae and anatomical areas involved
Minimal body weight of 50 kg
Able to communicate well with the investigator and understand and comply with the requirements of the study, and the ability and willingness to conduct study visits as per the study schedule
Use of other investigational drugs at the time of screening or before
Women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception
Pregnant or lactating women
Other protocol-defined inclusion/exclusion criteria may apply